Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Navtemadlin + TKI in R/R Ph+ CML
NCT04835584Phase 2Recruiting
- Sponsor
- Kartos Therapeutics
- Start
- May 2021
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 2 trial of navtemadlin in chronic myeloid leukemia (CML), sponsored by Kartos Therapeutics. Started May 2021; status: recruiting.
02
Drugs
navtemadlin
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT04835584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04835584.